| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 1, 2026 | Sun Pharma signs deal with US government to reduce drug prices | Drug major Sun Pharmaceutical Industries has signed a deal with the US government to lower prices of its innovative drugs in the US, in line with the lowest prices paid by other developed nations, under the most favoured nation (MFN) pricin... |
| Aug 26, 2026 | Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment | FDA IND Clearance for CBL-0201WR—Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide.
U.S. IRB Approval for Pivotal Phase 3 Trial SUPREME-01 (CBL-03... |
| Aug 26, 2026 | Interim Report for the period April – June 2026 | Interim Report for the period April – June 2026
Wed, Aug 26, 2026 08:00 CET Report this content
New approvals for Leqembi® and additional strategic partnerships
Events during the second quarter 2026 Eisai provided a sales forecast for Leqem... |
| Aug 25, 2026 | Amplifica Secures $26M for Hair Regeneration Breakthrough | Amplifica, a San Diego biopharma, just secured $26 million in Series B funding. This critical capital injection propels their innovative injectable therapies into advanced clinical development. The mission: reactivate dormant hair follicles... |
| Aug 25, 2026 | Innovent Announces 2026 Interim Results and Business Updates | Transforming from Regional Leader to Global Premier:
A Clear Strategic Path for Growth and Globalization
SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biophar... |
| Aug 24, 2026 | Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics | SEONGNAM, South Korea, Aug. 24, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego,... |
| Aug 20, 2026 | Amplifica Raises $26 Million Series B To Advance Injectable Hair Regrowth Therapies | Amplifica Holdings Group has raised an oversubscribed $26 million Series B financing to advance its pipeline of injectable therapies designed to reactivate dormant hair follicles and promote new hair growth. The financing was led by Tasso P... |
| Aug 18, 2026 | Hims & Hers CEO says FTC lawsuit misunderstands how the company works | Hims & Hers CEO Andrew Dudum defended the company against against an FTC lawsuit over its data sharing and subscription practices.
In an interview with CNBC, he also said the company’s sale of compounded GLP-1 drugs helped to bring pric... |
| Aug 17, 2026 | Daily Stock Market Live
S&P 500 falls for a third day, as elevated global bond yields and oil prices weigh on market | The S&P 500 fell on Tuesday, pressured by a run in sovereign bond yields to multi-year highs amid concerns of persistent inflation and elevated oil prices. A pullback in semiconductor stocks also weighed on the broader market.
The broad... |
| Aug 17, 2026 | Eli Lilly and J&J bounce on new data, as software stocks give up last week’s gains | |
| Aug 17, 2026 | Leal Therapeutics Raises $30M in Second Close of Series A Funding | Leal Therapeutics, a Worcester, MA-based provider of neuro-metabolic therapeutics for central nervous system disorders, raised $30M in the second close of its Series A funding.
Backers included Eli Lilly and Company, OrbiMed, Newpath Partne... |
| Aug 14, 2026 | Pharmaceuticals Market Trends: Innovation, Rising Healthcare Demand, and Advanced Therapies Driving Growth | The pharmaceuticals market is witnessing strong growth as rising healthcare needs, increasing disease prevalence, expanding access to medicines, and continuous innovation in drug development drive global demand. Pharmaceutical products play... |
| Aug 12, 2026 | The world's largest sovereign wealth fund revealed a $1.2 billion stake in SpaceX. Here's how much it holds of tech's biggest companies. | Norway's sovereign wealth fund, the world's largest, is the proud new owner of more than $1 billion in SpaceX stock.
The fund disclosed in the latest update of its holdings on Wednesday that, as of June 30, it owned a 0.05% stake in SpaceX,... |
| Aug 12, 2026 | Amplifica Raises $26M in Series B Funding | Amplifica Holdings Group, Inc., a San Diego, CA-based provider of clinical-stage biopharmaceutical therapies for hair growth, raised $26M in Series B financing.
The round was led by Tasso Partners, LLC, with participation from Eli Lilly and... |
| Aug 11, 2026 | Eli Lilly takes weight-loss pill battle global with first Foundayo approval in Europe | Eli Lilly’s Foundayo won U.K. approval, becoming Europe’s second GLP-1 weight-loss pill and its first approval in the continent
Foundayo will initially be available privately by prescription, with NHS access dependent on a cost-effectivenes... |
| Aug 10, 2026 | Remedium Bio Raises $10M in Initial Series A Funding | Remedium Bio, Inc., a Needham, MA-based provider of a gene therapy platform developing durable protein therapeutics, raised $10M in initial Series A financing.
The round was led by Lifespan Vision Ventures, with participation from Eli Lilly... |
| Aug 7, 2026 | A Cross Section of Company Statements Supporting Climate Action | Introduction
Over the past two years, the public conversation around corporate climate commitments has shifted considerably. Some companies that spoke openly about decarbonization have grown quieter, a phenomenon often described as “greenhu... |
| Aug 7, 2026 | Japan’s Ono Pharmaceutical Funds Fibrosis Discovery After Lilly’s $99M Bet on Same Biotech | By Morris Robinson
Published: Aug 07 2026, 1:47 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Aug 6, 2026 | The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings | Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks.
But while investors cheered Lilly’s results, they punished Novo a day earlier — underscoring a growing divide in Wall Street’s confidence in ... |
| Aug 6, 2026 |
Cramer’s lightning round: Buy Lockheed Martin | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Ameriprise Financial: “This thing is always... |
| Aug 6, 2026 |
Jim Cramer highlights 5 investing themes — and the stocks to buy for each | Monday - Friday, 6:00 - 7:00 PM ET
CNBC’s Jim Cramer said earnings season reinforced five investing themes he thinks will produce the market’s best buying opportunities.
He highlighted stocks to buy for each theme, including Capital One, Ra... |
| Aug 5, 2026 | Stocks making the biggest moves premarket: SpaceX, AMD, Eli Lilly, Disney & more | |
| Aug 5, 2026 | Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says | Bank of America CEO Brian Moynihan said the company is spending more than $250 million annually to provide GLP-1 weight loss medications to its workforce.
Moynihan told CNBC the expense has surged from zero about five years ago, but called ... |
| Aug 5, 2026 | Trading Day: The only way is up | ORLANDO, Florida, Aug 3 : World stocks leaped to record highs on Tuesday, boosted by a relentless stream of strong U.S. and global earnings, with another slump in oil prices on Middle East peace hopes pushing down on bond yields and boostin... |
| Aug 5, 2026 | We’re increasing our Eli Lilly price target after another beat-and-raise quarter | |
| Aug 4, 2026 | Eli Lilly Formalizes Retatrutide Access With Criteria Most Patients Cannot Meet | By Adrian Parham
Published: Aug 04 2026, 5:45 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Aug 3, 2026 | Ratio Therapeutics Raises $70M in Series C Funding | Ratio Therapeutics, a Boston, MA-based provider of a radiopharmaceutical platform developing targeted cancer treatments, raised $70M in Series C funding.
Backers included Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Managem... |
| Aug 3, 2026 | 5 Things to Know
U.S.-Iran talks, OpenAI’s Hugging Face hack, Best Buy’s new CEO and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Monday. I spent the weekend mostly outdoors at the Lollapalooza music festival in Chicago, but many others headed inside to catch the l... |
| Jul 31, 2026 | Deep Tech Reshapes Venture Capital: AI Infrastructure Commands Billions | Venture capital rapidly reorients. Major investments now target foundational infrastructure for the booming AI economy. This pivotal shift prioritizes hardware-heavy deep tech. Key sectors include advanced space technology, innovative clean... |
| Jul 31, 2026 | Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline | Novo Nordisk shares fell after its experimental medicine, ziltivekimab, failed to show a statistically meaningful reduction in major adverse cardiovascular events in patients with certain diseases.
“This does not change our strategic commit... |
| Jul 30, 2026 | Venture Capital & Startup Funding Roundup, July 30, 2026: Bessemer Venture Partners, G2 Venture Partners, ICONIQ Growth, Kleiner Perkins, Lightspeed & More | Tech investors are doubling down on the infrastructure underpinning today’s AI boom – from satellites in orbit to power-hungry data centers on Earth. The day’s largest deals span space tech, clean energy and AI-infused enterprise platforms,... |
| Jul 29, 2026 |
Cramer’s lightning round: Buy Astera Labs | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Astera Labs: “Nothing changed. It is just a... |
| Jul 28, 2026 | Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development Lifecycle | Norstella, the leading global provider of AI-enabled pharma intelligence solutions, announced the launch of the Pipeline-to-Patient Productivity Index, an annual benchmark measuring R&D productivity, market access, and commercial return... |
| Jul 24, 2026 | Pharmaceutical Frontier: Psychedelics Rise, GLP-1s Diversify, Global Innovation Thrives | The pharmaceutical industry undergoes rapid transformation. Big Pharma embraces psychedelic drugs, acquiring key innovators to treat diverse mental health conditions. This signals a new era for depression, PTSD, and anxiety therapies. Concu... |
| Jul 24, 2026 | Pharma Giants Clash Over GLP-1 Ad Truths | Novo Nordisk launched a major lawsuit against Eli Lilly. It alleges pervasive misleading advertising for Lilly’s prominent GLP-1 drugs, Zepbound and Mounjaro. Novo claims Lilly’s nationwide campaigns leverage outdated clinical trials. They ... |
| Jul 24, 2026 | Trump's Generic Drug Tariffs: U.S. Onshoring Push Faces Steep Challenges | U.S. faces major generic drug tariff changes. Trump announced duties up to 200% on imported generics. A two-year window encourages domestic manufacturing. This policy aims to onshore critical drug production. Industry concerns are high. Gen... |
| Jul 24, 2026 | Almirall H1 2026 Results | Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its financial results for the first half of 2026. The company delivered solid H1 2026 results, with Net Sales growing 7.5% YoY to €602.7... |
| Jul 24, 2026 | GIC’s 20-year annualised real return falls to 3.4%, lowest in 6 years | Listen
6 min
New: You can now listen to articles.
This audio is generated by an AI tool.
SINGAPORE: Sovereign wealth fund GIC's returns fell for a third straight year to a six-year low in FY2025/2026, as it took less risk and prioritised re... |
| Jul 24, 2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 30 June 2026 with key figures for the first three months of the 2026/2027 financial year |
Widespread strong performance
In the first quarter of the 2026/2027 financial year, HBM Healthcare Investments generated a profit of CHF 238 million. Once again, net assets exceeded the CHF 2 billion mark as at 30 June 2026.
The net asset ... |
| Jul 23, 2026 | Ozempic face? Botox boom boosted by ‘sagging face’ trend, Swiss firm says | The increasing rate of patients using GLP-1 medications is now boosting growth in Galderma’s aesthetics portfolio, CEO Flemming Ørnskov told CNBC on Thursday.
About 10% of U.S. adults now report taking GLP-1 drugs for weight loss, which may... |
| Jul 23, 2026 | Eli Lilly’s next-generation weight-loss shot clears another hurdle | Eli Lilly & Co.’s highly anticipated next-generation weight-loss shot didn’t increase overall heart risk in a new study, the company said, helping dispel lingering concerns over its potential as it nears regulatory review.
Lilly’s trial... |
| Jul 23, 2026 | Wall Street stumbles as oil surges, and Lilly takes a new path on next-gen obesity drug | |
| Jul 23, 2026 | Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH | BEIJING, July 23, 2026 /PRNewswire/ -- Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the Nati... |
| Jul 23, 2026 | Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials | Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials.
The drug delivered significant weight loss and improvements in a key meas... |
| Jul 22, 2026 | Trump plans generic drug tariffs from 2028 with two-year delay testing U.S. onshoring push | Trump said generic drugs imported into the U.S. will face zero tariffs for two years from August 1.
The rate will rise to 100% in 2028, before doubling a year later.
The latest tariff salvo underscored Trump’s goals of reshoring the low-cos... |
| Jul 22, 2026 | Trump’s generic drug tariffs: What they could mean for medicine prices, manufacturers and supply | Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing.
But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details r... |
| Jul 22, 2026 | Pharma heavyweights Novo Nordisk and Eli Lilly clash over anti-obesity drug ads | COPENHAGEN: Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday (Jul 21) it is suing arch US rival Eli Lilly over "false and materially misleading" adverts for its competing weight-loss and anti-diabetes treatments.
The D... |
| Jul 21, 2026 | Jim Cramer says he’s standing by Eli Lilly after rival’s GLP-1 lawsuit. Here’s why | |
| Jul 21, 2026 | Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising | Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy relative to the Danish drugmaker’s rival ... |
| Jul 21, 2026 | Novo Nordisk takes Eli Lilly to court over 'misleading' weight-loss drug ad | Here's what it said | Novo Nordisk said on Tuesday that it had filed a lawsuit against Eli Lilly in a US federal court, accusing the US drugmaker of falsely advertising its weight-loss drugs as being more effective than Novo Nordisk’s treatments.
Novo said in it... |
| Jul 19, 2026 | The market for psychedelic drugs to treat mental health conditions gets a big buy signal | To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo
Thursday’s announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma’s increasing embr... |
| Jul 18, 2026 | Chai Discovery Secures $400M, Propelling AI-Driven Molecular Design | Chai Discovery secured a $400 million Series C funding round. This elevates its valuation to $3.8 billion. The capital injection accelerates its AI-driven molecular design platform. Chai transforms drug discovery, shifting from trial-and-er... |
| Jul 18, 2026 | Fat cat? Weight-loss drugs may be coming for your overweight pet | Two U.S. biotech companies are testing experimental GLP-1 weight-loss treatments for overweight cats.
It marks one of the earliest attempts to bring the blockbuster drug class into pet medicine.
Analysts say the idea of GLP-1s for animals f... |
| Jul 17, 2026 | Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc. | Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc.
Fri, Jul 17, 2026 08:00 CET Report this content
17 July 2026
THE BIOTECH GROWTH TRUST PLC
(“BIOG” or the "Company")
Eli Lilly to acquire BIOG portfolio company, AtaiBec... |
| Jul 17, 2026 | Oura Secures Investment From Eli Lilly To Expand Connected Health Tools | Oura has received an equity investment from Eli Lilly and Company to accelerate the development of health tools that connect biometric information, daily behaviors and medical treatments. Financial terms of the investment were not disclosed... |
| Jul 16, 2026 | AdvanCell Closes $315 Million Series D |
BOSTON, MA, AdvanCell, a clinical-stage radiopharmaceutical company, announced the closing of an oversubscribed and upsized $315 million Series D financing.
>> Click here for more funding data on AdvanCell
>> To export AdvanCel... |
| Jul 16, 2026 | Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction | Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion.
AtaiBeckley is developing several psychedelics for mental health conditions.
The deal gives Lilly access to experimental drugs based on DMT and MDMA.
Eli Lilly will ... |
| Jul 16, 2026 | Trouble getting weight loss drugs covered by insurance? Here’s what to know | Getting your Trinity Audio player ready...
By Sydney Lupkin, KFF Health News
A professional in-home caregiver lost her coverage for Zepbound. She soon realized getting it back was not straightforward.
Deborah Finley, 50, of Lodi, California... |
| Jul 15, 2026 | Половые трудности | Половые трудности Почему растут продажи гормонов и смежных препаратов
Позднее родительство, развитие вспомогательных репродуктивных технологий (ВРТ), рост интереса мужчин к гормональной терапии и более осознанное отношение женщин к репродук... |
| Jul 15, 2026 | Camurus’ Interim Report Second Quarter 2026 | Camurus’ Interim Report Second Quarter 2026
Wed, Jul 15, 2026 07:00 CET Report this content
“Record product sales and strong operating performance”
Summary second quarter 2026
April – June
Total revenues increased 4% (3% at CER1) to MSEK 70... |
| Jul 15, 2026 | AdvanCell Closes US $315M in Series D Funding | AdvanCell, a Boston, MA- and Brisbane, Australia-based clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, raised US $315M Series D in funding.
The round was led by Ally Bridge Group and Alpha Wave, al... |
| Jul 15, 2026 | AdvanCell Closes $315 Million Series D Financing To Advance Targeted Alpha Therapies | AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, announced the closing of an oversubscribed and upsized $315 million Series D financing. The round was led by Ally Bridge Group and co-le... |
| Jul 14, 2026 | Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma | Chai Discovery Inc., a company that develops artificial intelligence models to predict interactions between biochemical molecules, today announced it has raised $400 million in new funding, nearly tripling its valuation to $3.8 billion.
Ind... |
| Jul 14, 2026 | Chai Discovery Raises $400 Million Series C To Advance AI-Driven Molecular Design | Chai Discovery announced a $400 million Series C financing to accelerate the development and deployment of its AI-driven molecular design platform. The round valued Chai Discovery at $3.8 billion. It was led by Index Ventures alongside Klei... |
| Jul 14, 2026 | Chai Discovery Raises $400M in Series C Funding | Chai Discovery, a San Francisco, CA-based company engineering AI models to discover new molecules, raised $400M in Series C funding.
The round, which valued the company at $3.8B, was led by Index Ventures alongside Kleiner Perkins, Sequoia ... |
| Jul 12, 2026 | AstraZeneca's Pipeline Premium Challenged After Wainua Trial Failure | AstraZeneca faced a rare clinical failure with its Wainua drug in a late-stage trial for ATTR cardiomyopathy. Shares plunged significantly, well beyond the drug's estimated financial impact. This event challenges the pharmaceutical giant's ... |
| Jul 11, 2026 | Alchemab Secures £25M Series A Extension, Fuels AI-Driven Antibody Pipeline | Alchemab Therapeutics landed a substantial £25M Series A extension. The British Business Bank led this pivotal investment. It pushes Alchemab's total Series A funding to an impressive £109M. This capital injection accelerates the Cambridge,... |
| Jul 11, 2026 | AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable? | AstraZeneca posted a rare clinical trial failure on Thursday, sending shares down 6% to their worst day in over two years.
Analysts estimate the trial miss wiped just 2-4% from their valuation models but the market reaction suggested it was... |
| Jul 10, 2026 | Alchemab Therapeutics Extends Series A Financing with USD34M | Alchemab Therapeutics, a Cambridge, UK-based clinical-stage biotechnology company, raised £25M (USD$34M) in Series A extension funding from British Business Bank.
Current investors included SV Health Investors and the Dementia Discovery Fun... |
| Jul 9, 2026 | Impressive growth of Eli Lilly’s obesity business is coming from all over the world | |
| Jul 9, 2026 | Alchemab Raises £25 Million Extension to Series A to Advance AI-Driven Antibody Pipeline | Clinical-stage biotechnology company Alchemab Therapeutics announced a £25 million (approximately $34 million) extension to its Series A financing from the British Business Bank. The investment marks the largest life sciences investment mad... |
| Jul 9, 2026 | Flare Therapeutics Secures $85M Series C Round |
CAMBRIDGE, MA, Flare Therapeutics, a clinical-stage biotechnology company, announced the closing of an $85 million Series C financing.
>> Click here for more funding data on Flare Therapeutics
>> To export Flare Therapeutics fu... |
| Jul 9, 2026 | Immunotherapy Drugs Market to Reach $580.6 Billion by 2029 | The global Immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, at a robust CAGR of 15.3% during the forecast period. Market growth is driven by advancements in antibody engineering te... |
| Jul 9, 2026 | Insilico Medicine Releases Positive Profit Alert for the First Half of 2026 | CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive prof... |
| Jul 7, 2026 | Terry Smith dubs weight-loss giant Novo Nordisk ‘investment disaster’ | Star stockpicker Terry Smith has dubbed weight-loss giant Novo Nordisk an “investment disaster” less than two years after he dumped his entire Diageo stake over fears that GLP-1 users would ditch alcohol.
The veteran investment manager, who... |
| Jul 6, 2026 | Ascletis Submits Two IND Applications to U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35 | - ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR.
- ASC36_35 FDC demonstrated ... |
| Jul 6, 2026 | Patent cliff fuels Novartis’ $1.5bn swoop for London biotech | Swiss pharmaceutical giant Novartis has agreed to buy London-based biotech Myricx Bio for up to $1.5bn (£1.1bn) as global drugmakers continue deploying billions into promising biotech firms ahead of an estimated $450bn wave of patent expiri... |
| Jul 6, 2026 | Daily Stock Market Live
Nasdaq futures fall as chip stocks struggle: Live updates | Nasdaq-100 futures fell Tuesday, weighed down by a decline in chip stocks as investors once again appear to rotate out of names tied to artificial intelligence.
Futures tied to the tech-heavy index were down 0.9%, while S&P 500 futures ... |
| Jul 4, 2026 | U.S. politician makes super suspicious SpaceX stock trade | United States Representative Gilbert Ray Cisneros has come under renewed attention after disclosing a purchase of SpaceX (NASDAQ: SPCX) stock shortly after the company’s blockbuster initial public offering (IPO).
According to filings, Cisne... |
| Jul 2, 2026 | Artan Bio Closes $1M Seed Funding Round | Artan Bio, a St. Petersburg, Florida-based developer of engineered transfer RNA (tRNA) therapies for mutation-driven aging biology, closed a $1m seed funding round.
The round was led by company co-founder Michael Torres, Ph.D., following hi... |
| Jul 1, 2026 | Medicare is now covering some GLP-1 weight loss drugs for $50. Here’s what to know | Getting your Trinity Audio player ready...
By ALI SWENSON
NEW YORK (AP) — Popular — and expensive — GLP-1 weight loss drugs just got a lot cheaper for many older Americans.
Starting Wednesday, the federal government is offering a selection ... |
| Jun 30, 2026 | Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China | SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| Jun 30, 2026 | 5 Things to Know
SCOTUS decisions, Dow at 52,000, the retirement savings gap and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Tuesday. As someone with protein coffee in their fridge, I can’t say I’m surprised that “functional beverages” are taking off.
Stock fu... |
| Jun 30, 2026 | Medicare will start covering obesity drugs for the first time. Here’s what patients should know | Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge.
The move could unlock a vast new patient population for Novo Nordisk and... |
| Jun 29, 2026 | Shanghai’s Annual Global AI Drug Discovery Contest Gets Underway | (Yicai) June 29 -- The Shanghai International Computational Biology Challenge, a global competition to find and promote talent in the field of artificial intelligence-based drug research and development, has kicked off, with the winners set... |
| Jun 29, 2026 | Lycia Therapeutics Raises $75M in Series D Funding | Lycia Therapeutics, a South San Francisco, California-based developer of extracellular protein degradation and lysosomal targeting chimera (LYTAC) therapeutics, raised $75m in Series D funding.
The round was co-led by Janus Henderson Invest... |
| Jun 29, 2026 | Lycia Therapeutics Raises $75 Million Series D To Advance LYTAC Pipeline | Lycia Therapeutics announced that it has completed an oversubscribed $75 million Series D financing. The financing was co-led by existing investor Janus Henderson Investors and new investor Balyasny Asset Management. The round also included... |
| Jun 29, 2026 | Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 29, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ther... |
| Jun 29, 2026 | Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities | Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s PreCheck pilot program, CNBC has learned.
The FDA PreCheck program is designed t... |
| Jun 28, 2026 | Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet | Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare’s new Bridge demonstration program for a monthly copay of just $50.
But many seniors may be unaware of the landmark shift starting on July 1,... |
| Jun 26, 2026 | Most of Wall Street rises, but sinking AI stocks send it lower for the week | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — Most of the U.S. stock market rose Friday after oil prices eased back to where they were before the war with Iran, but drops for stocks swept up in ... |
| Jun 26, 2026 | Stocks making the biggest moves midday: Moderna, ON Semiconductor, Rocket Lab, Eli Lilly, Sandisk & more | |
| Jun 26, 2026 | Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage | To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo
Novo Nordisk, the maker of Wegovy, introduced its GLP-1 pill for weight loss in early January, while Eli Lilly’s pill, Foundayo, began shipping in April.
In 2025, nearly h... |
| Jun 25, 2026 | Daily Stock Market Live
Nasdaq Composite posts fifth losing session Friday as chip stocks tumble: Live updates | The Nasdaq Composite posted its fifth consecutive losing session Friday as investors rotated out of key technology stocks and into more defensive areas of the market.
The tech-heavy index dropped 0.24% to close at 25,297.62, while the S&... |
| Jun 25, 2026 | Obesity drugs approach a major milestone, and Lilly may have a ‘game changer’ ahead | |
| Jun 25, 2026 | Anodyne Nanotech Raises $12.6 Million Series A To Advance Once-Weekly GLP-1 Patch | Anodyne Nanotech announced the closing of a $12.6 million Series A financing round to advance its once-weekly GLP-1 patch for obesity into Phase I clinical trials. The round was led by Velocity Partners VC and co-led by Evercurious VC, with... |
| Jun 24, 2026 | TRIMTECH Therapeutics Raises $47 Million Seed Funding To Advance Targeted Protein Degradation Portfolio | TRIMTECH Therapeutics announced that it has raised an additional $14 million in seed funding, bringing the total round to $47 million.
The additional financing was led by Johnson & Johnson’s corporate venture capital organization, Johns... |
| Jun 24, 2026 | Abbisko Therapeutics Deepens R&D Collaboration with Lilly | SHANGHAI, June 24, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with ... |
| Jun 24, 2026 | NYSE Content Update: Abridge Partners with Eli Lilly, Nvidia to Improve Healthcare | NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, June 24, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE P... |
